Methods for catheter-based renal denervation
Methods and apparatus are provided for treating end-stage renal disease, e.g., via a pulsed electric field, via a stimulation electric field, via localized drug delivery, via high frequency ultrasound, via thermal techniques, etc. Such neuromodulation may effectuate irreversible electroporation or electrofusion, necrosis and/or inducement of apoptosis, alteration of gene expression, action potential attenuation or blockade, changes in cytokine up-regulation and other conditions in target neural fibers. In some embodiments, neuromodulation is applied to neural fibers that contribute to renal function. In some embodiments, such neuromodulation is performed in a bilateral fashion. Bilateral renal neuromodulation may provide enhanced therapeutic effect in some patients as compared to renal neuromodulation performed unilaterally, i.e., as compared to renal neuromodulation performed on neural tissue innervating a single kidney.
1. A method for catheter-based renal neuromodulation, the method comprising:
positioning a catheter having a therapeutic element within a renal artery of a human patient; and
reducing neural traffic to and/or from a kidney of the patient via the therapeutic element,
wherein reducing the neural traffic to and/or from the kidney therapeutically treats a diagnosed condition or disease associated with cardio-renal function of the patient.
2. The method of claim 1 wherein reducing neural traffic to and/or from a kidney of the patient comprises blocking neural traffic to and/or from the kidney.
3. The method of claim 1 wherein reducing neural traffic to and/or from a kidney comprises transferring energy via the catheter with a renal nerve proximate to the renal artery.
4. The method of claim 3 wherein transferring energy via the catheter comprises ablating the renal nerve.
5. The method of claim 3 wherein transferring energy via the catheter comprises cooling the renal nerve.
6. The method of claim 3 wherein transferring energy via the catheter comprises delivering energy via the catheter to the renal nerve.
7. The method of claim 6 wherein delivering energy via the catheter to the renal nerve comprises delivering radiofrequency energy via the catheter to the renal nerve.
8. The method of claim 1 wherein reducing neural traffic to and/or from a kidney of the patient comprises denervating the kidney.
9. The method of claim 1 wherein reducing neural traffic to and/or from a kidney of the patient comprises modulating sympathetic nerves that innervate the kidney.
10. The method of claim 1 wherein positioning a catheter within a renal artery comprises positioning an electrode within the renal artery.
11. The method of claim 10 wherein positioning an electrode within the renal artery comprises placing the electrode in contact with a wall of the renal artery.
12. The method of claim 10 , further comprising monitoring contact between the electrode and the renal artery wall.
13. The method of claim 11 wherein monitoring contact between the electrode and the renal artery wall comprises monitoring impedance and/or temperature.
14. The method of claim 1 wherein positioning a catheter within a renal artery comprises positioning the catheter via a guide catheter.
15. The method of claim 1 wherein positioning a catheter within a renal artery comprises positioning the catheter using fluoroscopic guidance.
16. The method of claim 1 wherein reducing neural traffic to and/or from a kidney of the patient comprises reducing neural traffic via cryoablation.
17. The method of claim 1 wherein positioning a catheter within a renal artery comprises percutaneously, intravascularly, endovascularly or interventionally positioning the catheter within the renal artery.
18. A method for catheter-based renal denervation, the method comprising:
positioning a catheter having a therapeutic element within a renal artery of a human patient; and
ablating nerves that innervate a kidney of the patient via the therapeutic element,
wherein ablating the nerves results in a therapeutically beneficial reduction in blood pressure in the patient.
19. The method of claim 18 wherein positioning a catheter within a renal artery comprises positioning the catheter in a patient diagnosed with hypertension.
20. The method of claim 18 wherein positioning a catheter within a renal artery comprises positioning the catheter in a patient diagnosed with heart failure.
21. The method of claim 18 wherein positioning a catheter within a renal artery comprises positioning the catheter in a patient diagnosed with acute myocardial infarction.
22. The method of claim 18 wherein positioning a catheter within a renal artery comprises positioning the catheter in a patient diagnosed with kidney disease.
23. The method of claim 18 wherein positioning a catheter within a renal artery comprises positioning the catheter in a patient diagnosed with chronic renal failure.
24. The method of claim 18 wherein positioning a catheter within a renal artery comprises positioning the catheter in a patient diagnosed with a chronically activated sympathetic nervous system.
25. A method for catheter-based renal denervation, the method comprising:
positioning a catheter having a therapeutic element within a renal artery of a human patient; and
ablating nerves that innervate a kidney of the patient via the therapeutic element,
wherein ablating the nerves results in a therapeutically beneficial reduction in central sympathetic overactivity in the patient.
26. The method of claim 25 wherein the therapeutically beneficial reduction in central sympathetic overactivity comprises a reduction in clinical symptoms of hypertension in the patient.
27. The method of claim 25 wherein the therapeutically beneficial reduction in central sympathetic overactivity comprises a reduction in clinical symptoms of heart failure in the patient.
28. The method of claim 25 wherein the therapeutically beneficial reduction in central sympathetic overactivity comprises a reduction in clinical symptoms of chronic kidney disease in the patient.
29. The method of claim 25 wherein the therapeutically beneficial reduction in central sympathetic overactivity comprises a reduction in clinical symptoms of end stage renal disease in the patient.
30. The method of claim 25 wherein the therapeutically beneficial reduction in central sympathetic overactivity comprises a reduction in clinical symptoms of acute myocardial infarction in the patient.